WEBULL
News
NAMS
35.20
+0.34%
0.12
Top Executive’s Bold Move Sends Shockwaves Through NewAmsterdam Pharma
TipRanks · 12/30/2025 02:04
Weekly Report: what happened at NAMS last week (1222-1226)?
Weekly Report · 12/29/2025 10:15
Weekly Report: what happened at NAMS last week (1215-1219)?
Weekly Report · 12/22/2025 10:15
NewAmsterdam Pharma Is Maintained at Buy by Stifel
Dow Jones · 12/16/2025 17:38
NewAmsterdam Pharma Price Target Raised to $50.00/Share From $44.00 by Stifel
Dow Jones · 12/16/2025 17:38
Stifel Maintains Buy on NewAmsterdam Pharma Co, Raises Price Target to $50
Benzinga · 12/16/2025 17:28
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TipRanks · 12/16/2025 12:46
Weekly Report: what happened at NAMS last week (1208-1212)?
Weekly Report · 12/15/2025 10:21
National Presto, Garrett Motion, and More Stocks See Action From Activist Investors
Barron‘s · 12/12/2025 23:50
Weekly Report: what happened at NAMS last week (1201-1205)?
Weekly Report · 12/08/2025 10:20
Tracking Stanley Druckenmiller's Duquesne Family Office Portfolio - Q3 2025 Update
Seeking Alpha · 12/07/2025 23:56
NewAmsterdam Pharma Price Target Raised to $37.00/Share From $30.00 by Goldman Sachs
Dow Jones · 12/02/2025 18:24
NewAmsterdam Pharma Is Maintained at Neutral by Goldman Sachs
Dow Jones · 12/02/2025 18:24
Goldman Sachs Maintains Neutral on NewAmsterdam Pharma Co, Raises Price Target to $37
Benzinga · 12/02/2025 18:14
NewAmsterdam Pharma price target raised to $37 from $30 at Goldman Sachs
TipRanks · 12/02/2025 11:41
Weekly Report: what happened at NAMS last week (1124-1128)?
Weekly Report · 12/01/2025 10:16
Weekly Report: what happened at NAMS last week (1117-1121)?
Weekly Report · 11/24/2025 10:21
Weekly Report: what happened at NAMS last week (1110-1114)?
Weekly Report · 11/17/2025 10:20
NewAmsterdam: Obicetrapib MAA Filings Merit Continued 'Buy' Rating
Seeking Alpha · 11/16/2025 15:30
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
TipRanks · 11/11/2025 08:15
More
Webull provides a variety of real-time NAMS stock news. You can receive the latest news about NewAmsterdam Pharma Company N.V through multiple platforms. This information may help you make smarter investment decisions.
About NAMS
NewAmsterdam Pharma Company NV is a Netherlands based company. NewAmsterdam Pharma operates as a clinical-stage company and focuses on the research and development of transformative oral therapies for major cardiometabolic diseases. The Company is investigating obicetrapib, an oral, low-dose and once-daily, cholesteryl ester transfer protein (CETP) inhibitor, as the low-density lipoprotein cholesterol (LDL-C) lowering therapy to be used as an adjunct statin therapy for high-risk cardiovascular disease (CVD) patients. The Company is also testing obicetrapib as a fixed-dose combination therapy with ezetimibe in a secondary Phase 2 trial, ROSE2, for other diseases such as Alzheimer’s disease. The Company strives to offer its products around the world.